MESO Q1 2023 Earnings — Mesoblast Limited Revenue & Financial Results | Market Cap Arena

MESOMesoblast Limited

$2B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-59.8% YoY

Gross Profit

-$9M-635.3% margin

Operating Income

-$16M-1109.1% margin

Net Income

-$17M-1170.1% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-35.1%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$350,000

Balance Sheet

Total Assets

$684M

Total Liabilities

$162M

Stockholders' Equity

$523M

Cash & Equivalents

$85M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$4M	-59.8%
Gross Profit	-$9M	-$13M	+30.9%
Operating Income	-$16M	-$19M	+16.7%
Net Income	-$17M	-$23M	+25.4%